{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Sanjaisharma.jpg|frameless|upright=0.3|center]]
|<big>[[User:Sanjaisharma|Sanjai Sharma, MD]]<br>Visalia, CA</big>
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==[http://www.esmo.org/ ESMO]==
*'''2013:''' Dreyling et al. [https://academic.oup.com/annonc/article-abstract/24/4/857/260729/ESMO-Consensus-conferences-guidelines-on-malignant ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma] [https://www.ncbi.nlm.nih.gov/pubmed/23425945 PubMed]
*'''2013:''' Zucca et al. [https://www.esmo.org/Guidelines/Haematological-Malignancies/Gastric-Marginal-Zone-Lymphoma-of-MALT-Type Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
===Older===
*'''2009:''' Zucca et al. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdp146 Gastric marginal zone lymphoma of MALT type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/19454427 PubMed]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf NCCN Guidelines - B-cell Lymphomas]

=First-line therapy, randomized data=
''Note: This implies chemotherapy-naive. Some patients in the following studies, especially those with gastric MALT, received H. pylori eradication therapy or radiation prior to chemotherapy.''

==BR {{#subobject:ac973d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab
===Regimen {{#subobject:7926ac|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ Flinn et al. 2014 (BRIGHT)]
|style="background-color:#1a9851"|Phase III (E)
|1. [[#R-CHOP|R-CHOP]]<br> 2. [[#R-CVP|R-CVP]]
|style="background-color:#1a9850"|Superior PFS (*)
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(14)00021-0/fulltext Salar et al. 2014 (GELTAMO MALT2008-01)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|}
''Note: treatment in MALT2008-01 was response adapted; patients with CR after 3 cycles received a total of 4 cycles, whereas patients with PR after 3 cycles received a total of 6 cycles. Efficacy for '''BRIGHT''' is based on the 2017 update.''
====Chemotherapy====
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once on days 1 & 2
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications==== 
*Antiemetics, antipyretics, and antibiotics according to local standard of care
*Prophylactic use of [[:Category:Granulocyte colony-stimulating factors|G-CSF]] allowed according [http://jop.ascopubs.org/content/2/4/196.full ASCO guidelines] (2006)

'''28-day cycle for up to 8 cycles (see note)'''

===References===
<!-- # Ian Flinn et al. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. 2012 ASH Annual Meeting abstract 902. [https://ash.confex.com/ash/2012/webprogram/Paper51442.html link to abstract] -->
# '''BRIGHT:''' Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. [http://bloodjournal.org/content/123/19/2944.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24591201 PubMed]
## '''Update: Abstract:''' Ian Flinn, Richard van der Jagt, Julie E. Chang, Peter Wood, Tim E. Hawkins, David MacDonald, Judith Trotman, David Simpson, Kathryn S. Kolibaba, Samar Issa, Doreen M. Hallman, Ling Chen, and John M. Burke. First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. Journal of Clinical Oncology 2017 35:15_suppl, 7500-7500 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.7500 link to abstract]
# '''GELTAMO MALT2008-01:''' Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver FJ, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C; Grupo Español de Linfomas/Trasplante de Médula Ósea (GELTAMO). First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014 Dec;1(3):e104-11. Epub 2014 Nov 19. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(14)00021-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27029228 PubMed]
## '''Update:''' Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017 Oct 12;130(15):1772-1774. Epub 2017 Aug 11. [http://www.bloodjournal.org/content/130/15/1772.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28801448 PubMed]

==Chlorambucil monotherapy {{#subobject:10e826|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:fae569|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/31/3/301.full Leblond et al. 2012 (WM1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Fludarabine_monotherapy|Fludarabine]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] 8 mg/m<sup>2</sup> (6 mg/m<sup>2</sup> per day if older than 75 years old) PO once per day on days 1 to 10

====Supportive medications====
*Recommended PCP prophylaxis with ONE of the following:
**[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole (Bactrim SS)]] 1 tablet PO once per day 
**[[Pentamidine (Nebupent)]] 300 mg inhaled once per month

'''28-day cycle for up to 12 cycles'''

===Variant #2 {{#subobject:8fc8cb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Chlorambucil_.26_Rituximab|Chlorambucil & Rituximab]]
|style="background-color:#fc8d59"|Seems to have inferior PFS (*)
|-
|2. [[#Rituximab_monotherapy|Rituximab]]
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|}
''Note: reported efficacy is based on the 2017 update.''
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] 6 mg/m<sup>2</sup> PO once per day on days 1 to 42

'''One course'''
====Subsequent treatment====
*Patients with SD or better: [[#Chlorambucil_monotherapy_2|Chlorambucil consolidation]]

===References===
<!-- Presented at the 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 15-18, 2011, and at the 53th Annual Meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011. -->
# Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7. Epub 2012 Dec 10. [http://jco.ascopubs.org/content/31/3/301.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23233721 PubMed]
# '''IELSG-19:''' Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23295789 PubMed]
<!-- # '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] -->
## '''Update:''' Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.6994 link to original article][https://www.ncbi.nlm.nih.gov/pubmed/28355112 PubMed]

==Chlorambucil & Rituximab {{#subobject:346328|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:664c41|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)]
|style="background-color:#1a9851"|Phase III (E)
|1. [[#Chlorambucil_monotherapy|Chlorambucil]]<br> 2. [[#Rituximab_monotherapy|Rituximab]]
|style="background-color:#91cf60"|Seems to have superior PFS (*)
|-
|}
''Note: reported efficacy is based on the 2017 update.''
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] 6 mg/m<sup>2</sup> PO once per day on days 1 to 42
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

'''One course'''
====Subsequent treatment====
*Patients with SD or better: [[#Chlorambucil_.26_Rituximab_2|Chlorambucil & rituximab consolidation]]
===References===
# '''IELSG-19:''' Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23295789 PubMed]
<!-- # '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] -->
## '''Update:''' Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.6994 link to original article][https://www.ncbi.nlm.nih.gov/pubmed/28355112 PubMed]

==Fludarabine monotherapy {{#subobject:c6da52|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:5adb13|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/31/3/301.full Leblond et al. 2012 (WM1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Chlorambucil_monotherapy|Chlorambucil]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 40 mg/m<sup>2</sup> (30 mg/m<sup>2</sup> per day if older than 75 years old) PO once per day on days 1 to 5

====Supportive medications====
*Recommended PCP prophylaxis with ONE of the following:
**[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole (Bactrim SS)]] 1 tablet PO once per day 
**[[Pentamidine (Nebupent)]] 300 mg inhaled once per month
*Herpes zoster prophylaxis with ONE of the following:
**[[Valacyclovir (Valtrex)]] 500 mg PO once per day 
**[[Acyclovir (Zovirax)]] 200 to 400 mg PO twice per day 

'''28-day cycle for up to 6 cycles'''

===References===
<!-- Presented at the 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 15-18, 2011, and at the 53th Annual Meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011. -->
# Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7. Epub 2012 Dec 10. [http://jco.ascopubs.org/content/31/3/301.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23233721 PubMed]

==R-CHOP {{#subobject:f6aa15|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CHOP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
<br>R-CHOP-21: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone every '''<u>21</u>''' days
<br>CHOP-R: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>R</u>'''ituximab
====Example orders====
*[[Example orders for R-CHOP in lymphoma]]

===Regimen {{#subobject:a1629d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ Flinn et al. 2014 (BRIGHT)]
|rowspan=2 style="background-color:#91cf61"|Phase III, <20 in this arm (C)
|1. [[#BR|BR]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#R-CVP|R-CVP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*Antiemetics, antipyretics, and antibiotics per local standard of care
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] "according to the [http://jco.ascopubs.org/content/18/20/3558.full American Society of Clinical Oncology guidelines]"

'''21-day cycle for up to 8 cycles'''

===References===
<!-- # Ian Flinn et al. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. 2012 ASH Annual Meeting abstract 902. [https://ash.confex.com/ash/2012/webprogram/Paper51442.html link to abstract] -->
# Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. [http://bloodjournal.org/content/123/19/2944.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24591201 PubMed]
## '''Update: Abstract:''' Ian Flinn, Richard van der Jagt, Julie E. Chang, Peter Wood, Tim E. Hawkins, David MacDonald, Judith Trotman, David Simpson, Kathryn S. Kolibaba, Samar Issa, Doreen M. Hallman, Ling Chen, and John M. Burke. First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. Journal of Clinical Oncology 2017 35:15_suppl, 7500-7500 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.7500 link to abstract]

==R-CVP {{#subobject:2ba05b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CVP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisone

===Regimen {{#subobject:c0bc77|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ Flinn et al. 2014 (BRIGHT)]
|rowspan=2 style="background-color:#91cf61"|Phase III, <20 in this arm (C)
|1. [[#BR|BR]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#R-CHOP|R-CHOP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> or 1000 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*Antiemetics, antipyretics, and antibiotics per local standard of care
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] "according to the [http://jco.ascopubs.org/content/18/20/3558.full American Society of Clinical Oncology guidelines]"

'''21-day cycle for up to 8 cycles'''

===References===
<!-- # '''Abstract:''' Ian Flinn et al. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. 2012 ASH Annual Meeting abstract 902. [https://ash.confex.com/ash/2012/webprogram/Paper51442.html link to abstract] -->
# Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. [http://bloodjournal.org/content/123/19/2944.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24591201 PubMed]

==Rituximab monotherapy {{#subobject:c82d07|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:c20616|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://bloodjournal.hematologylibrary.org/content/102/8/2741.long Conconi et al. 2003 (IELSG 6)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://jco.ascopubs.org/content/23/9/1979.long Martinelli et al. 2005]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|rowspan=2|[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Chlorambucil_monotherapy|Chlorambucil]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Chlorambucil_.26_Rituximab|Chlorambucil & Rituximab]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900920/ Williams et al. 2016 (RESORT substudy)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week; initial infusion rate of 50 mg/H, then increased as tolerated by 50 mg/H every 30 minutes, to a maximum rate of 300 mg/H

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 650 mg PO 30 minutes prior to each dose
*[[Diphenhydramine (Benadryl)]] 50 mg PO 30 minutes prior to each dose

'''4-week course'''
====Subsequent treatment====
*RESORT substudy, patients with PR/CR: [[#Rituximab_monotherapy_2|Indefinite rituximab]] versus [[#Rituximab_monotherapy_3|salvage rituximab at time of progression]]

===References===
# Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. [http://bloodjournal.hematologylibrary.org/content/102/8/2741.long link to orginal article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12842999 PubMed] content property of [http://hemonc.org HemOnc.org]
# Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83. [http://jco.ascopubs.org/content/23/9/1979.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15668468 PubMed]
# '''IELSG-19:''' Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23295789 PubMed]
<!-- # '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] -->
## '''Update:''' Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.6994 link to original article][https://www.ncbi.nlm.nih.gov/pubmed/28355112 PubMed]
<!-- Presented in part at the American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, USA. -->
# '''RESORT substudy:''' Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900920/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26970533 PubMed]

=First-line therapy, non-randomized or retrospective data=
''Note: This implies chemotherapy-naive. Some patients in the following studies, especially those with gastric MALT, received H. pylori eradication therapy or radiation prior to chemotherapy.''

==Bortezomib monotherapy {{#subobject:8dbdb8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:f62265|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675689/ Troch et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.5 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11

====Supportive medications====
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] IV immediately before [[Bortezomib (Velcade)]]
*500 mL NS after [[Bortezomib (Velcade)]]

'''21-day cycle for up to 8 cycles'''

===References===
# Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. [http://www.haematologica.org/content/94/5/738.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675689/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19336742 PubMed]

==Cladribine monotherapy {{#subobject:b1fc89|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:501943|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/20/18/3872.long Jäger et al. 2002]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cladribine (Leustatin)]] 0.12 mg/kg IV over 2 hours once on days 1 to 5

'''28-day cycle for 4 to 6 cycles'''

====Dose reductions====
*"In case of a persisting nadir of the WBC count less than or equal to 4.0 × 10<sup>9</sup>/L (or ANC less than or equal to 1500/uL) and/or the platelets less than or equal to 100 × 10<sup>9</sup>/L, the next treatment cycle was delayed by 1 week until achieving normal values and then treatment was administered at a reduced dose of 0.1 mg/kg body weight."

===References===
# Jäger G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, Neumann HJ, Mlineritsch B, DeSantis M, Quehenberger F, Chott A, Beham-Schmid C, Höfler G, Linkesch W, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002 Sep 15;20(18):3872-7. [http://jco.ascopubs.org/content/20/18/3872.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12228207 PubMed]

==Cladribine & Rituximab {{#subobject:3ac33|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:bd61ae|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561434/ Troch et al. 2012]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cladribine (Leustatin)]] 0.1 mg/kg SC once per day on days 1 to 4
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 1000 mg PO prior to [[Rituximab (Rituxan)]]
*Antihistamine IV prior to [[Rituximab (Rituxan)]]
*Either [[Ondansetron (Zofran)]] or [[Tropisetron (Navoban)]] IV immediately before [[Cladribine (Leustatin)]]

'''21-day cycle for up to 6 cycles'''

===References===
# Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. [http://www.haematologica.org/content/98/2/264.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561434/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22983582 PubMed]

==Doxycycline monotherapy {{#subobject:342bb6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:2b7c1c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jnci.oxfordjournals.org/content/98/19/1375.long Ferreri et al. 2006]
|style="background-color:#ffffbe"|Phase II, <20 patients in this subgroup
|-
|[http://jco.ascopubs.org/content/30/24/2988.long Ferreri et al. 2012]
|style="background-color:#91cf61"|Phase II
|-
|}
''This treatment was intended for patients with ocular adnexal marginal zone lymphoma (OAMZL), given the association with Chlamydia psittaci.''
====Antibiotic therapy====
*[[Doxycycline]] 100 mg PO twice per day

'''3-week course'''

===References===
# Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, Dolcetti R. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82. [http://jnci.oxfordjournals.org/content/98/19/1375.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17018784 PubMed]
# Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, Montalbán C, Stelitano C, Cabrera ME, Giordano Resti A, Politi LS, Doglioni C, Cavalli F, Zucca E, Ponzoni M, Dolcetti R. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012 Aug 20;30(24):2988-94. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Nov 1;30(31):3903. [http://jco.ascopubs.org/content/30/24/2988.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22802315 PubMed]

==FR {{#subobject:413f96|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FR: '''<u>F</u>'''ludarabine & '''<u>R</u>'''ituximab
===Regimen {{#subobject:8551bb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.24605/full Salar et al. 2009]
|style="background-color:#91cf61"|Phase II
| style="background-color:#f7fcfd" |ORR: 100%
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV (or 40 mg/m<sup>2</sup> PO) once per day on days 1 to 5
**Patients with gastric lymphoma received the cycle 1 dose intravenously to guarantee drug absorption
**Patients greater than 70 years old: same dose, but only once per day on days 1 to 3
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole]] prophylaxis (dose/schedule not listed) per physician preference
*No routine antiviral prophylaxis or G-CSF use

'''28-day cycle for 4 to 6 cycles'''

===References===
# Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009 Nov 15;115(22):5210-7. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.24605/full link to orginal article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19672998 PubMed]

==Helicobacter pylori eradication therapy {{#subobject:be3ef5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:6a2469|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lancet/article/PII0140-6736(93)91409-F/fulltext Wotherspoon et al. 1993]
| style="background-color:#ffffbe" |Pilot
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(95)90113-2/fulltext Bayerdörffer et al. 1995]
| style="background-color:#91cf61" |Non-randomized
|-
|}
''To be completed''
====Antibiotic therapy====

===References===
# Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993 Sep 4;342(8871):575-7. [https://www.thelancet.com/journals/lancet/article/PII0140-6736(93)91409-F/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8102719 PubMed]
# Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte M; MALT Lymphoma Study Group. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet. 1995 Jun 24;345(8965):1591-4. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(95)90113-2/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7783535 PubMed]

==Ibritumomab tiuxetan monotherapy {{#subobject:cfb3aa|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:619265|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13021/full Samaniego et al. 2014]
|style="background-color:#ffffbe"|Phase II, <20 patients reported
|-
|[http://www.tandfonline.com/doi/full/10.3109/10428194.2014.975801 Lossos et al. 2014]
|style="background-color:#ffffbe"|Phase II, <20 patients reported
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 250 mg/m<sup>2</sup> IV once on day 1, then another single dose on day 8, '''given first on day 8'''
*[[Ibritumomab tiuxetan (Zevalin)|Ibritumomab tiuxetan & Yttrium-90 (Zevalin) ]] 14.8 MBq/kg (maximum dose of 1184 MBq) IV once on day 8, '''given second'''

'''One course of therapy'''

====Dose reductions====
*[[Ibritumomab tiuxetan (Zevalin)|Ibritumomab tiuxetan & Yttrium-90 (Zevalin) ]] 11.1 MBq/kg (maximum dose of 1184 MBq) for platelet count between 100 and 149 × 10<sup>9</sup>/L.

===References===
<!-- Study results were presented at 12th International Conference on Malignant Lymphoma Lugano, Switzerland, 2013. -->
# Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol. 2014 Oct;167(2):207-13. Epub 2014 Jul 8. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13021/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25040450 PubMed]
# Lossos IS, Fabregas JC, Koru-Sengul T, Miao F, Goodman D, Serafini AN, Hosein PJ, Stefanovic A, Rosenblatt JD, Hoffman JE. Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. Leuk Lymphoma. 2015 Jun;56(6):1750-5. Epub 2014 Nov 20. [http://www.tandfonline.com/doi/full/10.3109/10428194.2014.975801 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25315074 PubMed]

==Lenalidomide monotherapy {{#subobject:4f6ca7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:43bad7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.haematologica.org/content/98/3/353.long Kiesewetter et al. 2012]
|style="background-color:#ffffbe"|Phase II, <20 patients reported
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21

====Supportive medications====
*[[Aspirin]] 100 mg PO once per day

'''28-day cycle for up to 6 cycles'''

===References===
# Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. Epub 2012 Aug 16. [http://www.haematologica.org/content/98/3/353.long link to orginal article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659944/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22899582 PubMed]

==Lenalidomide & Rituximab {{#subobject:c8fa86|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:38dadd|Variant=1}}===

{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70455-3/fulltext Fowler et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|[http://www.bloodjournal.org/content/129/3/383.long Kiesewetter et al. 2016 (AGMT MALT-2)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 20 mg PO once per day on days 1 to 21
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 8 to 12 cycles'''

===References===
<!--
# '''Abstract:''' N. H. Fowler, P. McLaughlin, F. B. Hagemeister, L. W. Kwak, M. A. Fanale, S. S. Neelapu, L. Fayad, R. Z. Orlowski, M. Wang, F. Samaniego. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 28:15s, 2010 (suppl; abstr 8036). 2010 ASCO Annual Meeting abstract 8036. [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview==abst_detail_view&confID==74&abstractID==53803 link to abstract]
# '''Abstract:''' Nathan H Fowler, MD, Sattva S. Neelapu, MD, Fredrick B Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Robert Z. Orlowski, M.D., Ph.D., Michael Wang, M.D., Francesco Turturro, MD, Yasuhiro Oki, MD, Linda Catherine Lacerte, RN and Felipe Samaniego, MD, MPH. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. 2012 ASH Annual Meeting abstract 901. [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/901 link to abstract] -->
# Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov;15(12):1311-8. Epub 2014 Oct 15. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70455-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370362/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25439689 PubMed]
# Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, Mayerhoefer ME, Simonitsch-Klupp I, Melchardt T, Greil R, Raderer M; AGMT Investigators. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood. 2017 Jan 19;129(3):383-385. Epub 2016 Nov 22. [http://www.bloodjournal.org/content/129/3/383.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27879257 PubMed]

==MCP {{#subobject:1cc3da|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MCP: '''<u>M</u>'''itoxantrone, '''<u>C</u>'''hlorambucil, '''<u>P</u>'''rednisolone

===Regimen {{#subobject:2421bc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/14/12/1758.long Wöhrer et al. 2003]
|style="background-color:#ffffbe"|Retrospective
|-
|}
''Note: the chlorambucil dose is written in the reference as "3 x 3 mg/m<sup>2</sup>"; total dose per day is 9 mg/m<sup>2</sup>.''
====Chemotherapy====
*[[Mitoxantrone (Novantrone)]] 8 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Chlorambucil (Leukeran)]] 3 mg/m<sup>2</sup> PO three times per day on days 1 to 5
*[[Prednisolone (Millipred)]] 25 mg/m<sup>2</sup> IV or PO once per day on days 1 to 5

'''28-day cycle for up to 8 cycles'''

===References===
# '''Retrospective:''' Wöhrer S, Drach J, Hejna M, Scheithauer W, Dirisamer A, Püspök A, Chott A, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol. 2003 Dec;14(12):1758-61. [http://annonc.oxfordjournals.org/content/14/12/1758.long link to orginal article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14630681 PubMed]

==PCR {{#subobject:6b1b68|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PCR: '''<u>P</u>'''entostatin, '''<u>C</u>'''yclophosphamide, '''<u>R</u>'''ituximab

===Regimen {{#subobject:90e7f7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278955/ Samaniego et al. 2015]
|style="background-color:#ffffbe"|Phase II, <20 patients in this subgroup
|-
|}
====Chemotherapy====
*[[Pentostatin (Nipent)]] 4 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Ondansetron (Zofran)]] 8 mg (route not specified) prior to chemo
*[[Diphenhydramine (Benadryl)]] 25 mg (route not specified) prior to chemo
*500 ml of 5% dextrose/one-half normal saline before and after each pentostatin dose
*[[Filgrastim (Neupogen)]] at the discretion of the treating physician
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day on days 1 to 15 of cycle 1
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] once per day three days per week during and for 1 month following therapy
*[[Acyclovir (Zovirax)]] 400 mg PO twice per day during and for 1 month following therapy

'''21-day cycle for 6 cycles'''

===References===
# Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun;169(6):814-23. Epub 2015 Mar 31. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13367/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278955/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25828695 PubMed]

=Consolidation after first-line therapy=

==Chlorambucil monotherapy {{#subobject:0c174d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:9bb2aa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Chlorambucil_monotherapy|Chlorambucil induction]]
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] 6 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''28-day cycle for up to 4 cycles'''

===References===
# '''IELSG-19:''' Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23295789 PubMed]
<!-- # '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] -->
## '''Update:''' Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.6994 link to original article][https://www.ncbi.nlm.nih.gov/pubmed/28355112 PubMed]

==Chlorambucil & Rituximab {{#subobject:e72abc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:594e34|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/31/5/565.long Zucca et al. 2013 (IELSG-19)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Chlorambucil_.26_Rituximab|Chlorambucil & Rituximab induction]]
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] 6 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 4 cycles'''

===References===
# '''IELSG-19:''' Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/565.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23295789 PubMed]
<!-- # '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] -->
## '''Update:''' Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.6994 link to original article][https://www.ncbi.nlm.nih.gov/pubmed/28355112 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659366/ Hancock et al. 2008 (LY03)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Chlorambucil_monotherapy_2|Chlorambucil]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No further treatment.''
====Preceding treatment====
*[[#Helicobacter_pylori_eradication_therapy|H. pylori eradication therapy]]
===References===
# '''LY03:''' Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009 Feb;144(3):367-75. Epub 2008 Nov 22. [https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2008.07486.x link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659366/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19036078 PubMed]

==Rituximab monotherapy {{#subobject:1d6299|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:d2473c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900920/ Williams et al. 2016 (RESORT substudy)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Rituximab_monotherapy_3|Salvage rituximab]]
|style="background-color:#91cf60"|Seems to have superior TTTF
|-
|}
====Preceding treatment====
*[[#Rituximab_monotherapy|Rituximab]]
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 13 weeks

'''Continued indefinitely'''

===References===
<!-- Presented in part at the American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, USA. -->
# '''RESORT substudy:''' Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900920/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26970533 PubMed]

=Relapsed or refractory, non-randomized or retrospective data=

==Bendamustine monotherapy {{#subobject:ed6258|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:7c58ab|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2916680/ Kahl et al. 2010]
|style="background-color:#ffffbe"|Phase II, <20 patients reported
|-
|}
====Chemotherapy====
*[[Bendamustine]] 120 mg/m<sup>2</sup> IV once per day on days 1 & 2

'''21-day cycle for 6 to 8 cycles'''

===References===
<!-- Preliminary research findings from this study were presented at the 2007 American Society of Hematology Annual Meeting and Exposition, Atlanta, Georgia, December 8-11, 2007. -->
# Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010 Jan 1;116(1):106-14. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.24714/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2916680/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19890959 PubMed]

==Bortezomib monotherapy {{#subobject:448e81|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1 {{#subobject:583593|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/22/3/689.long Conconi et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11

====Supportive medications====
*No routine growth factors, antibiotic, or antiviral prophylaxis was given

'''21-day cycle for up to 6 cycles'''

===Variant #2 {{#subobject:fd9bf5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675689/ Troch et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|}

*[[Bortezomib (Velcade)]] 1.5 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11

====Supportive medications====
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] IV immediately before [[Bortezomib (Velcade)]]
*500 mL NS after [[Bortezomib (Velcade)]]

'''21-day cycle for up to 8 cycles'''

===References===
# Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. [http://www.haematologica.org/content/94/5/738.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675689/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19336742 PubMed]
# Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E; International Extranodal Lymphoma Study Group (IELSG). Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 2011 Mar;22(3):689-95. [http://annonc.oxfordjournals.org/content/22/3/689.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20810546 PubMed]

==BR {{#subobject:9b8c84|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab

===Regimen {{#subobject:c98fa0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/23/15/3383.long Rummel et al. 2005]
|style="background-color:#ffffbe"|Phase II, <20 patients in this subgroup
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**One week prior to start of cycle 1: 375 mg/m<sup>2</sup> IV once
**Cycles 1 to 4: 375 mg/m<sup>2</sup> IV once on day 1
**4 weeks after cycle 4: 375 mg/m<sup>2</sup> IV once
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 2 & 3

'''28-day cycle for 4 cycles'''

===References===
# Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005 May 20;23(15):3383-9. [http://jco.ascopubs.org/content/23/15/3383.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15908650 PubMed]

==Cladribine & Rituximab {{#subobject:bedbe7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:d0a8c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561434/ Troch et al. 2012]
|style="background-color:#ffffbe"|Phase II, <20 patients reported
|-
|}
====Chemotherapy====
*[[Cladribine (Leustatin)]] 0.1 mg/kg SC once per day on days 1 to 4
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 1000 mg PO prior to [[Rituximab (Rituxan)]]
*Antihistamine IV prior to [[Rituximab (Rituxan)]]
*Either [[Ondansetron (Zofran)]] or [[Tropisetron (Navoban)]] IV immediately before [[Cladribine (Leustatin)]]

'''21-day cycle for up to 6 cycles'''

===References===
# Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. [http://www.haematologica.org/content/98/2/264.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561434/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22983582 PubMed]

==Clarithromycin monotherapy {{#subobject:bfabe7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:a1a8c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/26/8/1760.full Ferreri et al. 2015 (HD-K)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Antibiotic therapy====
*[[Clarithromycin (Biaxin)]] 2 g PO once per day on days 1 to 14

'''21-day cycle for 4 cycles'''

===References===
# Ferreri AJ, Sassone M, Kiesewetter B, Govi S, Scarfò L, Donadoni G, Raderer M. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. Ann Oncol. 2015 Aug;26(8):1760-5. Epub 2015 May 1. [http://annonc.oxfordjournals.org/content/26/8/1760.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25935794 PubMed]

==Doxycycline monotherapy {{#subobject:1a9a25|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:d575c3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jnci.oxfordjournals.org/content/98/19/1375.long Ferreri et al. 2006]
|style="background-color:#ffffbe"|Phase II, <20 patients in this subgroup
|-
|}
''This treatment was intended for patients with ocular adnexal marginal zone lymphoma (OAMZL), given the association with Chlamydia psittaci.''
====Antibiotic therapy====
*[[Doxycycline]] 100 mg PO twice per day

'''3-week course'''

===References===
# Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, Dolcetti R. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82. [http://jnci.oxfordjournals.org/content/98/19/1375.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17018784 PubMed]

==Idelalisib monotherapy {{#subobject:1c0cad|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
'''On 3/21/2016 Gilead announced that they were stopping seven clinical trials of idelalisib in patients with CLL, SLL, and iNHL due to excess deaths and increased rates of SAEs. A [http://www.zydeligrems.com/ REMS program] has also been announced.'''

===Regimen, {{#subobject:9da677|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039496/ Gopal et al. 2014 (DELTA)]
|style="background-color:#ffffbe"|Phase II, <20 patients in this subgroup
|-
|}
====Chemotherapy====
*[[Idelalisib (Zydelig)]] 150 mg PO twice per day

'''Continued indefinitely'''

===References===
# Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kd Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. N Engl J Med. 2014 Jan 22. [https://www.nejm.org/doi/full/10.1056/NEJMoa1314583 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039496/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24450858 PubMed]
## '''Update:''' '''Abstract:''' Ajay K. Gopal, MD, Brad S. Kahl, MD, Sven de Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Wojciech Jurczak, MD, PhD, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, Kristie A. Blum, MD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, PhD, Leanne M. Holes, Bess Sorensen, PhD, Wayne R. Godfrey, MD and Gilles Andre Salles, MD, PhD. Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). ASH Annual Meeting 2014, Abstract 1708 [https://ash.confex.com/ash/2014/webprogram/Paper74940.html link to abstract]

==Ibrutinib monotherapy {{#subobject:af879d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b44969|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399483/ Noy et al. 2017 (PCYC-1121-CA)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#8c96c6" |ORR: 48% (95% CI, 35-62)
|-
|}
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 560 mg PO once per day

'''Continued indefinitely'''

===References===
<!-- #'''Abstract:''' Ariela Noy, MD, PhD, Sven de Vos, MD, PhD, Catherine Thieblemont, MD, PhD, Peter Martin, MD, Christopher Flowers, MD, MS, Franck Morschhauser, MD, PhD, Graham P. Collins, MD, PhD, Shuo Ma, Morton Coleman, MD, Shachar Peles, MD, Stephen Smith, MD, Alina Smith, Brian Munneke, PhD, Isaiah Dimery, MD, Darrin Beaupre, MD, PhD and Robert W Chen, MD. Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study. ASH 2016 Annual Meeting Abstract 1213. [https://ash.confex.com/ash/2016/webprogram/Paper89393.html link to abstract] [https://clinicaltrials.gov/ct2/show/NCT01980628 ClinicalTrials.gov info] -->
# '''PCYC-1121-CA:''' Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017 Apr 20;129(16):2224-2232. Epub 2017 Feb 6. [http://www.bloodjournal.org/content/129/16/2224.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399483/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28167659 PubMed]

==Lenalidomide monotherapy {{#subobject:2b1ccb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:f1de78|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.haematologica.org/content/98/3/353.long Kiesewetter et al. 2012]
|style="background-color:#ffffbe"|Phase II, <20 patients reported
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21

====Supportive medications====
*[[Aspirin]] 100 mg PO once per day

'''28-day cycle for up to 6 cycles'''

===References===
# Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. Epub 2012 Aug 16. [http://www.haematologica.org/content/98/3/353.long link to orginal article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659944/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22899582 PubMed]

==Ox-P {{#subobject:401729|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Ox-P: '''<u>Ox</u>'''aliplatin & '''<u>P</u>'''rednisone
===Regimen {{#subobject:675076|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.tandfonline.com/doi/full/10.3109/10428194.2015.1099650 Oh et al. 2016 (CISL)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: the treatment details state that prednisone was used, but later in the text prednisolone is mentioned. The authors have been contacted for clarification.''
====Chemotherapy====
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5 (see note)

'''21-day cycle for up to 6 cycles'''

===References===
# Oh SY, Kim WS, Kim JS, Chae YS, Lee GW, Eom HS, Ryoo HM, Lee S, Kim SJ, Yoon DH, Won JH, Hong J, Park J, Lee SM, Hong JY, Park E, Kim HJ, Yang DH, Kim HJ, Suh C. A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. Leuk Lymphoma. 2016;57(6):1406-12. [http://www.tandfonline.com/doi/full/10.3109/10428194.2015.1099650 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26413982 PubMed]

==Rituximab monotherapy {{#subobject:29dc8b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:73277c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://bloodjournal.hematologylibrary.org/content/102/8/2741.long Conconi et al. 2003]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://jco.ascopubs.org/content/23/9/1979.long Martinelli et al. 2005]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900920/ Williams et al. 2016 (RESORT substudy)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy_2|Maintenance rituximab]]
|style="background-color:#fc8d59"|Seems to have inferior TTTF
|-
|}
====Preceding treatment====
*RESORT substudy: [[#Rituximab_monotherapy|Rituximab]], with progression
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

'''One course'''

===References===
# Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. [http://bloodjournal.hematologylibrary.org/content/102/8/2741.long link to orginal article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12842999 PubMed]
# Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83. [http://jco.ascopubs.org/content/23/9/1979.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15668468 PubMed]
<!-- Presented in part at the American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, USA. -->
# '''RESORT substudy:''' Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14007/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900920/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26970533 PubMed]

==Vorinostat monotherapy {{#subobject:1d4752|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:f64907|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083875/ Kirschbaum et al. 2011]
|style="background-color:#ffffbe"|Phase II, <20 pts in subgroup
|-
|}
====Chemotherapy====
*[[Vorinostat (Zolinza)]] 200 mg PO twice per day on days 1 to 14

'''21-day cycles'''

===References===
# Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Mar 20;29(9):1198-203. Epub 2011 Feb 7. [http://jco.ascopubs.org/content/29/9/1198.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083875/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21300924 PubMed]

=Prognosis=

==MALT-IPI (2017)==
===Risk factors===
*Stage III or IV
*Age older than 70 years
*LDH greater than the upper limit of normal
===Calculation===
*'''Low risk:''' zero risk factors present
*'''Intermediate risk:''' one risk factor present
*'''High risk:''' two or more risk factors present
===References===
# Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, Martelli M, Laszlo D, Coiffier B, Lopez Guillermo A, Torri V, Cavalli F, Johnson PW, Zucca E. A MALT lymphoma prognostic index. Blood. 2017 Sep 21;130(12):1409-1417. Epub 2017 Jul 18. [http://www.bloodjournal.org/content/130/12/1409.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28720586 PubMed]

=Response criteria=

==NCI Sponsored International Working Group Criteria (1999)==
# Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr;17(4):1244. Review. Erratum in: J Clin Oncol 2000 Jun;18(11):2351. [http://jco.ascopubs.org/content/17/4/1244.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10561185 PubMed]

[[Category:Marginal zone lymphoma regimens]]
[[Category:MALT lymphoma regimens]]
[[Category:Disease-specific pages]]
[[Category:Indolent lymphomas]]
